The firm maintains a vulnerable capital structure with an accumulated deficit of $410.6 million and minimal tangible assets, evidenced by net property, plant, and equipment of only $6.7 million as of 2026Q1.
| Total Current Assets | 394.61M | 265.45M | 347.46M | 211.67M | 257.29M | 304.06M | 15.28M | 127K |
| Cash & Short-Term Investments | 383.47M | 256M | 341.44M | 203.47M | 251.21M | 302.18M | 15.22M | 108K |
| Cash Only | 84.95M | 77.39M | 91.97M | 58.01M | 251.21M | 302.18M | 15.22M | 108K |
| Short-Term Investments | 298.51M | 178.62M | 249.47M | 145.46M | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 2M | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - |
| Other Current Assets | 11.15M | 9.45M | 4.02M | 8.2M | 6.08M | 0 | 0 | 0 |
| Total Non-Current Assets | 17.43M | 17.16M | 16.09M | 14.19M | 8.89M | 2.64M | 730K | 401K |
| Property, Plant & Equipment | 6.66M | 6.89M | 7.72M | 8.15M | 3.54M | 2.09M | 466K | 276K |
| Fixed Asset Turnover | 0.00x | - | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 1M | 0 | 0 | 0 | 0 | 0 | 243K | 0 |
| Other Non-Current Assets | 10.77M | 10.27M | 8.38M | 6.03M | 5.35M | 555K | 21K | 125K |
| Total Assets | 412.04M | 282.61M | 363.56M | 225.86M | 266.18M | 306.7M | 16.01M | 528K |
| Asset Turnover | 0.00x | - | - | - | - | - | - | - |
| Asset Growth % | -41.07% | -22.27% | 60.97% | -15.15% | -13.21% | 1815.56% | 2932.39% | - |
| Total Current Liabilities | 19.26M | 18.09M | 14.59M | 15.33M | 5.7M | 3.62M | 1.86M | 5.16M |
| Accounts Payable | 3.64M | 1.18M | 590K | 4.66M | 1.15M | 599K | 664K | 327K |
| Days Payables Outstanding | 5.99K | - | - | - | - | - | 5.16K | 14.92K |
| Short-Term Debt | 488K | 472K | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 15.13M | 16.44M | 13.59M | 5.27M | 0 | 0 | 278K | 4.33M |
| Current Ratio | 20.49x | 14.67x | 23.81x | 13.80x | 45.13x | 84.09x | 8.22x | 0.02x |
| Quick Ratio | 20.49x | 14.67x | 23.81x | 13.80x | 45.13x | 84.09x | 8.22x | 0.02x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 5.21M | 5.34M | 5.81M | 6.26M | 2.65M | 1.35M | 27.79M | 114K |
| Long-Term Debt | 5.21M | 5.34M | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 11.04M | 0 | 5.81M | 6.22M | 2.48M | 981K | 0 | 114K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 3K | 46K | 169K | 367K | 27.79M | 0 |
| Total Liabilities | 24.46M | 23.43M | 20.41M | 21.59M | 8.35M | 4.96M | 29.65M | 5.27M |
| Total Debt | 5.7M | 5.81M | 6.22M | 6.5M | 2.62M | 1.18M | 142K | 253K |
| Net Debt | -79.26M | -71.58M | -85.74M | -51.51M | -248.59M | -301M | -15.08M | 145K |
| Debt / Equity | 0.01x | 0.02x | 0.02x | 0.03x | 0.01x | 0.00x | - | - |
| Debt / EBITDA | -0.04x | - | - | - | - | - | - | - |
| Net Debt / EBITDA | 0.56x | - | - | - | - | - | - | - |
| Interest Coverage | - | - | - | - | - | - | -9335.00x | -3122.00x |
| Total Equity | 387.57M | 259.18M | 343.15M | 204.26M | 257.83M | 301.74M | -13.64M | -4.74M |
| Equity Growth % | -46.9% | -24.47% | 68% | -20.78% | -14.55% | 2312.47% | -187.66% | - |
| Book Value per Share | 6.28 | 4.35 | 6.00 | 4.78 | 6.16 | 7.28 | -0.32 | -0.11 |
| Total Shareholders' Equity | 387.57M | 259.18M | 343.15M | 204.26M | 257.83M | 301.74M | -13.64M | -4.74M |
| Common Stock | 6K | 5K | 5K | 4K | 4K | 4K | 0 | 0 |
| Retained Earnings | -410.56M | -371.26M | -251.31M | -164.83M | -95.7M | -40.37M | -14.08M | -4.74M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 107K | 393K | 770K | 381K | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Clinical Trial Funding Dependency
As reported in recent financial statements, TYRA's total assets have declined from $404.7 million in 2024Q1 to $412.0 million in 2026Q1, while the accumulated deficit has ballooned to $410.6 million, signaling a trajectory of persistent capital consumption that necessitates frequent and dilutive external financing rounds.
The balance sheet reflects a company in a state of perpetual capital depletion, where asset growth is entirely dependent on equity issuance rather than internal value creation. Investors should monitor the widening gap between the accumulated deficit and total equity, as this trend suggests that the company's core platform development is consuming capital at an accelerating rate.
Based on the provided quarterly data, TYRA's cash position has fluctuated significantly, dropping from a peak of $254.4 million in 2024Q1 to $85.0 million by 2026Q1, which indicates a narrowing runway as the company intensifies its clinical trial activities and operational expenditures.
While the current ratio remains high at 20.49, this metric is somewhat misleading for a pre-revenue biotech, as it does not account for the high burn rate associated with clinical trial execution. The volatility in cash levels suggests that the company is highly sensitive to capital market conditions, and any delay in clinical milestones could force management to seek dilutive financing sooner than anticipated.
According to the company's balance sheet, equity has been sustained primarily through capital raises, yet the persistent growth in the accumulated deficit to $410.6 million as of 2026Q1 highlights the ongoing erosion of shareholder value through non-cash stock-based compensation and operational losses.
The reliance on equity as the primary funding source suggests that existing shareholders face significant dilution risk as the company continues to fund its R&D pipeline. The lack of retained earnings indicates that the business model is not yet self-sustaining, making the equity base highly sensitive to the perceived probability of clinical success.
As indicated by the reported figures, the company's asset base is almost entirely composed of cash and minimal property, plant, and equipment, with net PPE of only $6.7 million as of 2026Q1, leaving little tangible collateral to support the firm's long-term operational requirements.
The absence of significant tangible assets or intellectual property valuation on the balance sheet means that the company's enterprise value is almost entirely speculative. Investors should be aware that the lack of hard assets provides no downside protection, and the company's survival is tethered exclusively to the clinical outcomes of its lead candidate.
Quick answers to the most common questions about buying TYRA stock.
As of 2025, Tyra Biosciences, Inc. (TYRA) had total assets of $282.6M including $265.4M in current assets.
Tyra Biosciences, Inc. (TYRA) carries total debt of $5.8M, offset by $256.0M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Tyra Biosciences, Inc. (TYRA) has total shareholders' equity (book value) of $259.2M ($4.35 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Tyra Biosciences, Inc. (TYRA) reported a current ratio of 14.67x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.